The biological implication of cancer stem cells in hepatocellular carcinoma: a possible target for future therapy

References

• El-SeragHB, Rudolph KL. . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7), 2557–2576 (2007).
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 94(2), 153–156 (2001).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 362(9399), 1907–1917 (2003).
   PubMed Web of Science ®Google Scholar
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908–943 (2012).
   PubMed Web of Science ®Google Scholar
• Bruix J, Llovet JM. HCC surveillance: who is the target population? Hepatology 37(3), 507–509 (2003).
   PubMed Web of Science ®Google Scholar
• Roskams T. Different types of liver progenitor cells and their niches. J. Hepatol. 45(1), 1–4 (2006).
   PubMed Web of Science ®Google Scholar
• Ma S, Chan KW, Hu L et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132(7), 2542–2556 (2007).
   PubMed Web of Science ®Google Scholar
• Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 27(12), 1749–1758 (2008).
   PubMed Web of Science ®Google Scholar
• Yin S, Li J, Hu C et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer. 120(7), 1444–1450 (2007).
   PubMed Web of Science ®Google Scholar
• Yang ZF, Ho DW, Ng MN et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13(2), 153–166 (2008).
   PubMed Web of Science ®Google Scholar
• Yang ZF, Ngai P, Ho DW et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 47(3), 919–928 (2008).
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ji J, Budhu A et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 136(3), 1012–1024 (2009).
   PubMed Web of Science ®Google Scholar
• Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 9(1), 5063 (2011.
   Google Scholar
• Yamashita T, Honda M, Nakamoto Y et al. Discrete nature of EpCAM(+) and CD90(+) cancer stem cells in human hepatocellular carcinoma. Hepatology 57(4), 1484–1497 (2013).
   PubMedGoogle Scholar
• Yang W, Wang C, Lin Y et al. OV6(+) tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J. Hepatol. 57(3), 613–620 (2012).
   PubMed Web of Science ®Google Scholar
• Haraguchi N, Ishii H, Mimori K et al. CD13 is a therapeutic target in human liver cancer stem cells. J. Clin. Invest. 120(9), 3326–3339 (2010).
   PubMed Web of Science ®Google Scholar
• Zhu Z, Hao X, Yan M et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int. J. Cancer. 126(9), 2067–2078 (2010).
   PubMed Web of Science ®Google Scholar
• Ma S, Chan KW, Lee TK et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol. Cancer Res. 6(7), 1146–1153 (2008).
   PubMed Web of Science ®Google Scholar
• Cao L, Zhou Y, Zhai B et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC. Gastroenterol. 11, 71 (2011.
   PubMed Web of Science ®Google Scholar
• Hu X, Ghisolfi L, Keates AC et al. Induction of cancer cell stemness by chemotherapy. Cell Cycle 11(14), 2691–2698 (2012.
   PubMed Web of Science ®Google Scholar
• Haraguchi N, Utsunomiya T, Inoue H et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 24(3), 506–513 (2006).
   PubMed Web of Science ®Google Scholar
• Haraguchi N, Inoue H, Tanaka F et al. Cancer stem cells in human gastrointestinal cancers. Hum. Cell. 19(1), 24–29 (2006).
   PubMedGoogle Scholar
• Chiba T, Kita K, Zheng YW et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 44(1), 240–251 (2006).
   PubMed Web of Science ®Google Scholar
• Oikawa T, Kamiya A, Zeniya M et al. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology 57(4), 1469–1483 (2013).
   PubMed Web of Science ®Google Scholar
• Ho DW, Yang ZF, Yi K et al. Gene expression profiling of liver cancer stem cells by RNA-sequencing. PLoS ONE 7(5), e37159 (2012.
   Google Scholar
• Piao LS, Hur W, Kim TK et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 315(2), 129–137 (2012).
   PubMed Web of Science ®Google Scholar
• Lan X, Wu YZ, Wang Y et al. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells. Int. J. Mol. Med. 31(2), 315–324 (2013).
   PubMedGoogle Scholar
• Colombo F, Baldan F, Mazzucchelli S et al. Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma. PLoS ONE 6(6), e21369 (2011.
   Google Scholar
• Wilson GS, Hu Z, Duan W et al. Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterizing Liver Cancer Stem Cells. Stem Cells. Dev. 22(19), 2655–2664 (2013)
   PubMedGoogle Scholar
• Lee JS, Chu IS, Heo J et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 40(3), 667–676 (2004).
   PubMed Web of Science ®Google Scholar
• Lee JS, Heo J, Libbrecht L et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 12(4), 410–416 (2006).
   PubMed Web of Science ®Google Scholar
• Yamashita T, Forgues M, Wang W et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 68(5), 1451–1461 (2008).
   PubMed Web of Science ®Google Scholar
• Yu XH, Xu LB, Liu C, Zhang R, Wang J. Clinicopathological characteristics of 20 cases of hepatocellular carcinoma with bile duct tumor thrombi. Dig. Dis. Sci. 56(1), 252–259 (2011).
   PubMedGoogle Scholar
• Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ, Hu RM. Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. Acta Histochem. 113(8), 833–838 (2011).
   PubMedGoogle Scholar
• Song W, Li H, Tao K et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int. J. Clin. Pract. 62(8), 1212–1218 (2008).
   PubMed Web of Science ®Google Scholar
• Sasaki A, Kamiyama T, Yokoo H et al. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol. Rep. 24(2), 537–546 (2010).
   Google Scholar
• Lingala S, Cui YY, Chen X et al. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp. Mol. Pathol. 89(1), 27–35 (2010).
   PubMedGoogle Scholar
• Zeng Z, Ren J, O'Neil M et al. Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation. BMC Cancer. 12, 584 (2012.
   PubMed Web of Science ®Google Scholar
• Salnikov AV, Kusumawidjaja G, Rausch V et al. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett. 275(2), 185–193 (2009).
   PubMed Web of Science ®Google Scholar
• Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC, Wong J. Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. Ann. Surg. 254(4), 569–576 (2011).
   PubMed Web of Science ®Google Scholar
• Ho JW, Pang RW, Lau C et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44(4), 836–843 (2006).
   PubMedGoogle Scholar
• Sun YF, Xu Y, Yang XR et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 57(4), 1458–1468 (2013).
   PubMed Web of Science ®Google Scholar
• He XC, Yin T, Grindley JC et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat. Genet. 39(2), 189–198 (2007).
   PubMedGoogle Scholar
• Hu C, Li H, Li J et al. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis. 29(12), 22892297 (2008.
   Google Scholar
• Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt- beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 67(22), 10831–10839 (2007).
   PubMed Web of Science ®Google Scholar
• Yang W, Yan HX, Chen L et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 68(11), 4287–4295 (2008).
   PubMed Web of Science ®Google Scholar
• Cheung RS, Brooling JT, Johnson MM, Riehle KJ, Campbell JS, Fausto N. Interactions between MYC and transforming growth factor alpha alter the growth and tumorigenicity of liver progenitor cells. Carcinogenesis 28(12), 2624–2631 (2007).
   PubMedGoogle Scholar
• Zhao Y, Jian W, Gao W et al. RNAi silencing of c-Myc inhibits cell migration, invasion, and proliferation in HepG2 human hepatocellular carcinoma cell line: c-Myc silencing in hepatocellular carcinoma cell. Cancer Cell Int. 13(1), 23 (2013.
   Google Scholar
• Wandzioch E, Zaret KS. Dynamic signaling network for the specification of embryonic pancreas and liver progenitors. Science 324(5935), 1707–1710 (2009).
   PubMed Web of Science ®Google Scholar
• Wu K, Ding J, Chen C et al. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 56(6), 2255–2267 (2012).
   PubMed Web of Science ®Google Scholar
• Amin R, Mishra LLiver stem cells and tgf-Beta in hepatic carcinogenesis. Gastrointest. Cancer Res. 2(Suppl. 4), S27–S30 (2008.
   Google Scholar
• Tang Y, Kitisin K, Jogunoori W et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF- beta and IL-6 signaling. Proc. Natl Acad. Sci. U.S.A. 105(7), 2445–2450 (2008).
   PubMed Web of Science ®Google Scholar
• Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 432(7015), 324–331 (2004).
   PubMed Web of Science ®Google Scholar
• Cheng WT, Xu K, Tian DY, Zhang ZG, Liu LJ, Chen Y. Role of Hedgehog signaling pathway in proliferation and invasiveness of hepatocellular carcinoma cells. Int. J. Oncol. 34(3), 829–836 (2009).
   PubMedGoogle Scholar
• Huang S, He J, Zhang X et al. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis. 27(7), 1334–1340 (2006).
   PubMed Web of Science ®Google Scholar
• Chen X, Lingala S, Khoobyari S, Nolta J, Zern MA, Wu J. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J. Hepatol. 55(4), 838–845 (2011).
   PubMedGoogle Scholar
• Tanimizu N, Miyajima A. Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. J. Cell Sci. 117(Pt. 15), 3165–3174 (2004.
   PubMedGoogle Scholar
• Nijjar SS, Crosby HA, Wallace L, Hubscher SG, Strain AJ. Notch receptor expression in adult human liver: a possible role in bile duct formation and hepatic neovascularization. Hepatology 34(6), 1184-1192 (2001.
   Google Scholar
• Villanueva A, Alsinet C, Yanger K et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 143(6), 1660–1669 (2012).
   PubMed Web of Science ®Google Scholar
• Gao J, Dong Y, Zhang B et al. Notch1 activation contributes to tumor cell growth and proliferation in human hepatocellular carcinoma HepG2 and SMMC7721 cells. Int. J. Oncol. 41(5), 1773–1781 (2012).
   PubMedGoogle Scholar
• Ahn S, Hyeon J, Park CK. Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma. Hepatobiliary. Pancreat. Dis. Int. 12(3), 286–294 (2013).
   PubMedGoogle Scholar
• Nishina S, Shiraha H, Nakanishi Y et al. Restored expression of the tumor suppressor gene RUNX3 reduces cancer stem cells in hepatocellular carcinoma by suppressing Jagged1-Notch signaling. Oncol. Rep. 26(3), 523–531 (2011).
   Google Scholar
• Tanaka S, Shiraha H, Nakanishi Y et al. Runt-related transcription factor 3 reverses epithelial- mesenchymal transition in hepatocellular carcinoma. Int. J. Cancer. 131(11), 2537–2546 (2012).
   PubMedGoogle Scholar
• Zhao J, Ma MZ, Ren H et al. Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy. Clin. Cancer Res. 19(13), 3567–3576 (2013).
   Google Scholar
• Llovet JM, Bruix J Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48(4), 1312 1327 (2008.
   Google Scholar
• Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J. Hepatol. 56(6), 1371–1383 (2012).
   PubMedGoogle Scholar
• Chai S, Ma S. Clinical implications of miRNAs in liver cancer stem cells. Chin. J. Cancer 32(8), 419–426 (2013).
   PubMed Web of Science ®Google Scholar
• Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid. Res. 42(7), 1007–1017 (2001).
   PubMed Web of Science ®Google Scholar
• Goodell MA. Stem cell identification and sorting using the Hoechst 33342 side population (SP). Curr. Protoc. Cytom., Chapter 9, Unit 9 (2005).
   Google Scholar
• Zhou S, Schuetz JD, Bunting KD et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7(9), 10281034 (2001.
   Google Scholar
• Shi GM, Xu Y, Fan J et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J. Cancer Res. Clin. Oncol. 134(11), 1155–1163 (2008).
   PubMed Web of Science ®Google Scholar
• Sun Z, Zhao Z, Li G et al. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori 96(1), 90–96 (2010).
   PubMedGoogle Scholar
• Sukowati CH, Rosso N, Pascut D et al. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterol. 12, 160 (2012.
   PubMed Web of Science ®Google Scholar
• Vander Borght S, van Pelt J, van Malenstein H et al. Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro. Hepatol. Res. 38(11), 1112–1121 (2008).
   Google Scholar
• Chen Z, Liu F, Ren Q et al. Suppression of ABCG2 inhibits cancer cell proliferation. Int. J. Cancer. 126(4), 841–851 (2010).
   PubMedGoogle Scholar
• Durnez A, Verslype C, Nevens F et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 49(2), 138–151 (2006).
   PubMedGoogle Scholar
• Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. Semin Cancer Biol. 21(1), 35–43 (2010).
   PubMedGoogle Scholar
• Lindner U, Kramer J, Rohwedel J, Schlenke P. Mesenchymal Stem or Stromal Cells: Toward a Better Understanding of Their Biology? Transfus. Med. Hemother. 37(2), 75–83 (2010).
   PubMed Web of Science ®Google Scholar
• Olumi AF, Grossfeld GD, Hayward SW, Caroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59(19), 5002–5011 (1999).
   PubMed Web of Science ®Google Scholar
• Liu L, Dai Y, Chen J et al. Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition via Akt/GSK-3beta/snail signaling. Hepatology doi:10.1002/hep.26677 (2013) (Epub ahead of print).
   Google Scholar
• Henrich CJ, Bokesch HR, Dean M et al. A high-throughput cell-based assay for inhibitors of ABCG2 activity. J. Biomol Screen. 11(2), 176–183 (2006).
   PubMedGoogle Scholar
• Henrich CJ, Budhu A, Yu Z et al. High-throughput Screening for Identification of Inhibitors of EpCAM- Dependent Growth of Hepatocellular Carcinoma Cells. Chem. Biol. Drug. Des. 82(2), 131–139 (2013).
   PubMedGoogle Scholar
• Chiba T, Suzuki E, Negishi M et al. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int. J. Cancer. 130(11), 2557–2567 (2012).
   PubMed Web of Science ®Google Scholar
• Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Gianelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 51(2), 523–534 (2010).
   PubMed Web of Science ®Google Scholar
• de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J. Hepatol. 56(Suppl. 1), S75–S87 (2012).
   Google Scholar
• Zhang L, Sun H, Zhao F et al. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Res. 72(16), 4276–4285 (2012).
   PubMedGoogle Scholar
• Nagano H, Ishii H, Marubashi S et al. Novel therapeutic target for cancer stem cells in hepatocellular carcinoma. J. Hepatobiliary. Pancreat. Sci. 19(6), 600–605 (2012).
   PubMedGoogle Scholar